Gannie Tzoneva

Gannie Tzoneva

Auto-generated profile, based on publicly available information

Gannie Tzoneva

Regeneron Genetics Center, Tarrytown, NY, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2013 in Nature Medicine
Verified
Journal Article
Open access
PDF file
GTGannie Tzoneva
Gannie Tzoneva
APArianne Perez-Garcia
Arianne Perez-Garcia
ZCZachary Carpenter
Zachary Carpenter
HKHossein Khiabanian
Hossein Khiabanian
VTValeria Tosello
Valeria Tosello
AFAdolfo Ferrando
Adolfo Ferrando
Mutations in the cytosolic 5′-nucleotidase II gene accelerate the inactivation of chemotherapeutic nucleoside analogs in acute lymphoblastic leukemia (ALL)-promoting lymphoblasts. Increased nucleotide metabolism may therefore constitute an important resistance mechanism in chemotherapy-resilient ALL. Acute lymphoblastic leukemia (ALL) is an aggressive hematological tumor resulting from the malignant transformation of lymphoid progenitors. Despite intensive chemotherapy, 20% of pediatric patients and over 50% of adult patients with ALL do not achieve a complete remission or relapse after intensified chemotherapy, making disease relapse and resistance to therapy the most substantial challenge in the treatment of this disease1,2. Using whole-exome sequencing, we identify mutations in the cytosolic 5′-nucleotidase II gene (NT5C2), which encodes a 5′-nucleotidase enzyme that is responsible for the inactivation of nucleoside-analog chemotherapy drugs, in 20/103 (19%) relapse T cell ALLs and 1/35 (3%) relapse B-precursor ALLs. NT5C2 mutant proteins show increased nucleotidase activity in vitro and conferred resistance to chemotherapy with 6-mercaptopurine and 6-thioguanine when expressed in ALL lymphoblasts. These results support a prominent role for activating mutations in NT5C2 and increased nucleoside-analog metabolism in disease progression and chemotherapy resistance in ALL.

21 September 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
KOKoichi Oshima
Koichi Oshima
HKHossein Khiabanian
Hossein Khiabanian
ASAna C. da Silva-Almeida
Ana C. da Silva-Almeida
GTGannie Tzoneva
Gannie Tzoneva
FAFrancesco Abate
Francesco Abate
AFAdolfo A. Ferrando
Adolfo A. Ferrando
Although multiagent combination chemotherapy is curative in a significant fraction of childhood acute lymphoblastic leukemia (ALL) patients, 20% of cases relapse and most die because of chemorefractory disease. Here we used whole-exome and whole-genome sequencing to analyze the mutational landscape at relapse in pediatric ALL cases. These analyses identified numerous relapse-associated mutated genes intertwined in chemotherapy resistance-related protein complexes. In this context, RAS-MAPK pathway-activating mutations in the neuroblastoma RAS viral oncogene homolog (NRAS), kirsten rat sarcoma viral oncogene homolog (KRAS), and protein tyrosine phosphatase, nonreceptor type 11 (PTPN11) genes were present in 24 of 55 (44%) cases in our series. Interestingly, some leukemias showed retention or emergence of RAS mutant clones at relapse, whereas in others RAS mutant clones present at diagnosis were replaced by RAS wild-type populations, supporting a role for both positive and negative selection evolutionary pressures in clonal evolution of RAS-mutant leukemia. Consistently, functional dissection of mouse and human wild-type and mutant RAS isogenic leukemia cells demonstrated induction of methotrexate resistance but also improved the response to vincristine in mutant RAS-expressing lymphoblasts. These results highlight the central role of chemotherapy-driven selection as a central mechanism of leukemia clonal evolution in relapsed ALL, and demonstrate a previously unrecognized dual role of RAS mutations as drivers of both sensitivity and resistance to chemotherapy. Significance Relapsed acute lymphoblastic leukemia (ALL) is associated with chemotherapy resistance and poor prognosis. This study analyzes the emergence of acquired mutations in relapsed ALL samples, identifying genes implicated in disease progression and defining the process of clonal evolution leading to relapse. These analyses revealed that ALL relapse emerges from subclonal populations sharing only part of the mutations present in the dominant leukemia population found at diagnosis. Moreover, we show mutations in genes implicated in chemotherapy resistance pathways at relapse. RAS mutations are highly prevalent in high-risk ALL, yet their capacity to confer resistance to methotrexate and sensitivity to vincristine, two core drugs used in the treatment of ALL, influences their positive or negative selection at relapse.

11 May 2015 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
BLBenshang Li
Benshang Li
HLHui Li
Hui Li
YBYun Bai
Yun Bai
RKRenate Kirschner-Schwabe
Renate Kirschner-Schwabe
JYJun J Yang
Jun J Yang
BZBin-Bing S Zhou
Bin-Bing S Zhou

17 January 2018 in Nature
Verified
Journal Article
Closed access
PDF file
GTGannie Tzoneva
Gannie Tzoneva
CDChelsea L. Dieck
Chelsea L. Dieck
KOKoichi Oshima
Koichi Oshima
AAAlberto Ambesi-Impiombato
Alberto Ambesi-Impiombato
MSMarta Sánchez-Martín
Marta Sánchez-Martín
AFAdolfo A. Ferrando
Adolfo A. Ferrando

1 July 2018 in Cancer Cell
Verified
Journal Article
Closed access
CDChelsea L. Dieck
Chelsea L. Dieck
GTGannie Tzoneva
Gannie Tzoneva
FFFarhad Forouhar
Farhad Forouhar
ZCZachary Carpenter
Zachary Carpenter
AAAlberto Ambesi-Impiombato
Alberto Ambesi-Impiombato
AFAdolfo A. Ferrando
Adolfo A. Ferrando

7 June 2012
Verified
Book Chapter
Closed access
PDF file
GTGannie Tzoneva
Gannie Tzoneva
AFAdolfo A. Ferrando
Adolfo A. Ferrando